Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts).

被引：0
|
作者：
Kazushi, Yoshida
Inoue, Akira
Sugawara, Shunichi
Murakami, Shuji
Saka, Hideo
Morita, Satoshi
Kim, Young Hak
Imamura, Fumio
Takeda, Koji
Nakagawa, Kazuhiko
Takeda, Masayuki
Atagi, Shinji
Hasegawa, Yoshikazu
Yamamoto, Nobuyuki
Katakami, Nobuyuki
Yoshioka, Hiroshige
Iwamoto, Yasuo
Okamoto, Isamu
Seto, Takashi
Ohe, Yuichiro
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[3] Sendai Kousei Hosp, Sendai, Miyagi, Japan
[4] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[5] Nagoya Med Ctr, Nagoya, Aichi, Japan
[6] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[7] Kyoto Univ Hosp, Kyoto, Japan
[8] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pulm Oncol, Osaka, Japan
[9] Osaka City Gen Hosp, Dept Med Oncol, Osaka, Japan
[10] Kinki Univ, Sch Med, Osaka, Japan
[11] Kinki Univ, Fac Med, Dept Med Oncol, Osaka, Japan
[12] Kinki Chuo Chest Med Ctr, Osaka, Japan
[13] Kinki Univ, Sakai Hosp, Sch Med, Sakai, Osaka, Japan
[14] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
[15] Inst Biomed Res & Innovat, Div Integrated Oncol, Kobe, Hyogo, Japan
[16] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan
[17] Hiroshima City Hosp, Dept Med Oncol, Hiroshima, Japan
[18] Kyushu Univ Hosp, Fukuoka, Japan
[19] Natl Kyushu Canc Ctr, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e20503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20503
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Overall Survival (OS) of EGFR Mutation Positive Non-Small Cell Lung Cancer Patients: Real-World Treatment Patterns of 1,660 Japanese Patients
    Yoshida, Kazushi
    Ohe, Yuichiro
    Inoue, Akira
    Kumagai, Toru
    Takeda, Masayuki
    Yamamoto, Nobuyuki
    Seto, Takashi
    Okamoto, Isamu
    Tashiro, Naoki
    Morita, Satoshi
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S336 - S337
  • [2] Overall survival (OS) of EGFR mutation-positive nonsmall cell lung cancer (NSCLC): 1,660 Japanese patients (pts)
    Yoshioka, Hiroshige
    Sugawara, Shunichi
    Yoshida, Kazushi
    Murakami, Shuji
    Kim, Young Hak
    Atagi, Shinji
    Imamura, Fumio
    Takeda, Koji
    Seto, Takashi
    Morita, Satoshi
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
    Kazuo Tamura
    Toshihiro Nukiwa
    Akihiko Gemma
    Nobuyuki Yamamoto
    Masaya Mizushima
    Kaori Ochai
    Rie Ikeda
    Hisaya Azuma
    Yoichi Nakanishi
    International Journal of Clinical Oncology, 2019, 24 : 917 - 926
  • [4] Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
    Tamura, Kazuo
    Nukiwa, Toshihiro
    Gemma, Akihiko
    Yamamoto, Nobuyuki
    Mizushima, Masaya
    Ochai, Kaori
    Ikeda, Rie
    Azuma, Hisaya
    Nakanishi, Yoichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (08) : 917 - 926
  • [5] Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
    Kazuo Tamura
    Toshihiro Nukiwa
    Akihiko Gemma
    Nobuyuki Yamamoto
    Masaya Mizushima
    Kaori Ochai
    Rie Ikeda
    Hisaya Azuma
    Yoichi Nakanishi
    International Journal of Clinical Oncology, 2019, 24 : 1169 - 1169
  • [6] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
    Alsharedi, M.
    Bukamur, H.
    Elhamdani, A.
    DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
  • [7] Impact of afatinib dosing on safety and efficacy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) in a real-world setting
    Halmos, Balazs
    Tan, Eng-Huat
    Soo, Ross
    Cadranel, Jacques
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward
    Melosky, Barbara
    Maerten, Angela
    Carcereny, Enric
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 160 - 161
  • [8] Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Funazo, T.
    Yasuda, Y.
    Hirai, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2416 - S2416
  • [9] Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib
    Yao, Zong-Han
    Liao, Wei-Yu
    Ho, Chao-Chi
    Chen, Kuan-Yu
    Shih, Jin-Yuan
    Chen, Jin-Shing
    Lin, Zhong-Zhe
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    Yu, Chong-Jen
    ONCOLOGIST, 2017, 22 (09): : 1075 - 1083
  • [10] Effect of EGFR amplification on survival of patients with EGFR mutation-positive non-small cell lung cancer.
    Xu, Yiquan
    Wang, Haibo
    Zheng, Xinlong
    Lin, Gen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345